Hansen Medical to Exhibit Magellan(TM) Robotic System at Upcoming CACVS & LINC Meetings in Europe
23 1월 2014 - 10:00PM
Marketwired
Hansen Medical to Exhibit Magellan(TM) Robotic System at Upcoming
CACVS & LINC Meetings in Europe
MOUNTAIN VIEW, CA--(Marketwired - Jan 23, 2014) - Hansen
Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular
robotics, today announced it will exhibit its Magellan™ Robotic
System at two upcoming interventional meetings in Europe.
Hansen will be exhibiting Magellan at Booth 25 for the
Controversies and Updates in Vascular Surgery (CACVS) Meeting in
Paris, France from January 23 - 25; and at Booth 4 for the Leipzig
Interventional Course (LINC) in Leipzig, Germany from January 28 -
31.
Multiple physicians are scheduled to give presentations about
their experiences with Magellan at these meetings. Dr.
Frederic Cochennec of Henri Mondor Hospital in Créteil, France will
speak about his center's experiences with Magellan on Friday,
January 24 at 8:40 a.m. Two additional presentations are
scheduled for LINC. Professor Nick Cheshire, medical director
at Imperial College Healthcare NHS Trust in London, will present a
session titled "Can robotic assistance be helpful to navigate
through complex arch anatomies and make CAS safer?" on Tuesday,
January 28 at 5:40 p.m.; and Dr. Thomas Nolte, Director of Vascular
Center, Heart & Vascular Center, Bad Bevensen, Germany will
present "Robotic routing in complex aortic intervention" during the
moderated poster presentation session on Wednesday, January 29 at
10:20 a.m.
"We are excited to showcase the Magellan Robotic System at these
important global conferences," said Bruce Barclay, president and
CEO of Hansen Medical. "Approximately 5,000 interventionalists from
around the world are expected to attend these two meetings, and
these presentations by physicians representing multiple European
institutions will provide important information to the
interventional community about the clinical value Magellan is
delivering in a wide variety of peripheral vascular
procedures."
About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used
to facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices. The Magellan System is designed to deliver
predictability to simple and complex endovascular procedures. Since
its commercial introduction in the U.S. and Europe, the Magellan
System has demonstrated its clinical versatility in many cases in a
broad variety of peripheral vascular procedure types in centers
across the US and Europe. The system is based upon the flexible
robotic technology incorporated in the Sensei-X® Robotic
Catheter System currently sold in the U.S. and Europe, which has
been used in nearly 13,000 patients, but includes a number of key
enhancements. In particular, the Magellan Robotic System:
- Provides solid catheter stability for placement of therapeutic
devices.
- Is designed to enable predictable procedure times and increased
case throughput.
- Allows for independent, individual robotic control of the
distal tips of both the outer sheath and the inner leader catheter,
as well as robotic manipulation of standard guidewires.
- Is designed to allow for sufficient extension inside the body
to access hard to reach peripheral anatomy.
- Preserves the open architecture featured in the Sensei System
to allow for the subsequent use of many 6F therapeutic devices on
the market today.
- Is designed to potentially reduce physician radiation exposure
and fatigue by employing a remote physician workstation.
About Hansen Medical, Inc. Hansen Medical, Inc., based
in Mountain View, California, is a global leader in intravascular
robotics, developing products and technology designed to enable the
accurate positioning, manipulation and control of catheters and
catheter-based technologies. The Company's Magellan™ Robotic
System, 9Fr Magellan™ Robotic Catheter and related accessories,
which are intended to facilitate navigation to anatomical targets
in the peripheral vasculature and subsequently provide a conduit
for manual placement of therapeutic devices, have undergone both CE
marking and 510(k) clearance and are commercially available in the
European Union, and the U.S. In the European Union, the Company's
Sensei® X Robotic Catheter System and Artisan®
and Artisan Extend® Control Catheters are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the
Lynx® Robotic Ablation Catheter is cleared for the
treatment of AF. This robotic catheter system is compatible with
fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S., the Company's Sensei X Robotic
Catheter System and Artisan and Artisan Extend Control Catheters
are cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the U.S., the Sensei X Robotic Catheter System is
not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X Robotic Catheter
System and Artisan and Artisan Extend Control Catheter for use with
cardiac ablation catheters in the treatment of cardiac arrhythmias,
including AF, have not been established. Additional information can
be found at www.hansenmedical.com.
Forward-Looking Statements This press release contains
forward-looking statements regarding, among other things,
statements relating to goals, plans, objectives, milestones and
future events. All statements, other than statements of historical
fact, are statements that could be deemed forward-looking
statements, including statements containing the words "plan,"
"expects," "potential," "believes," "goal," "estimate,"
"anticipates," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date
of this press release and are subject to risks, uncertainties,
changes in circumstances and other factors that may cause actual
results to differ materially from the information expressed or
implied by forward-looking statements made in this press release.
Examples of such statements include statements about the potential
benefits of our technology and the value of our intellectual
property portfolio. Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for
the sales cycle for newly introduced products; the rate of adoption
of our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our
products; competition from other companies; our ability to recruit
and retain key personnel; our ability to manage expenses and cash
flow, and obtain additional financing; and other risks more fully
described in the "Risk Factors" section of our Quarterly Report on
Form 10-Q for the quarter ended September 30, 2013 filed with the
SEC on November 8, 2013 and the risks discussed in our other
reports filed with the SEC. Given these uncertainties, you should
not place undue reliance on the forward-looking statements in this
press release. We undertake no obligation to revise or update
information herein to reflect events or circumstances in the
future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial Officer
Hansen Medical, Inc. 650.404.5800 FTI Consulting, Inc. Brian
Ritchie 212.850.5683 Email Contact John Capodanno 212.850.5705
Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024